DynaGen Inc. on Monday said it has filed to begin Phase IIclinical trials of its NicErase System for smoking cessation.
NicErase is a non-nicotine substance that acts on the nicotinereceptors in the brain. It uses the company's biopolymer-basedcontrolled release drug delivery system.
"This is a weekly subcutaneous injection which takes care ofthe compliance and abuse issue that exists with the patch andthe gum," said Jack Barlow, senior vice president for corporateplanning.
According to Barlow, injections maintain proper blood levels ofthe therapeutic, whereas affixing more than the appropriatenumber of nicotine patches or chewing more than therecommended amount of nicotine gum can raise the amountabove therapeutic levels.
DynaGen stock (NASDAQ:DYGN) closed unchanged at $7.88 onMonday. -- Jeffrey M. Freedman
(c) 1997 American Health Consultants. All rights reserved.